authors
- Voors, Adriaan A
- Lanius, Vivian
- van der Laan, Michael
- Solomon, Scott D
- Shah, Sanjiv J
- Bax, Jeroen J
- Butler, Javed
- Gheorghiade, Mihai
- Hernandez, Adrian F
- Dalane W Kitzman, MD
- McMurray, John J V
- Wirtz, Antonieta Bomfim
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2018
published in
has subject area
- Adenosine A1 Receptor Agonists
- Adolescent
- Adult
- Aged
- Clinical Trials, Phase II as Topic
- Dipeptides
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Follow-Up Studies
- Heart Failure
- Heart Rate
- Humans
- Male
- Middle Aged
- Multicenter Studies as Topic
- Pyridines
- Randomized Controlled Trials as Topic
- Stroke Volume
- Treatment Outcome
- Ventricular Function, Left
- Young Adult